CA2310621A1 - Procede d'evaluation des effets toxiques et pathologiques de stimuli environnementaux sur la transcription des genes - Google Patents
Procede d'evaluation des effets toxiques et pathologiques de stimuli environnementaux sur la transcription des genes Download PDFInfo
- Publication number
- CA2310621A1 CA2310621A1 CA002310621A CA2310621A CA2310621A1 CA 2310621 A1 CA2310621 A1 CA 2310621A1 CA 002310621 A CA002310621 A CA 002310621A CA 2310621 A CA2310621 A CA 2310621A CA 2310621 A1 CA2310621 A1 CA 2310621A1
- Authority
- CA
- Canada
- Prior art keywords
- genes
- gene
- mammal
- mrna
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 85
- 230000007613 environmental effect Effects 0.000 title claims abstract description 34
- 238000013518 transcription Methods 0.000 title claims abstract description 30
- 230000035897 transcription Effects 0.000 title claims abstract description 30
- 231100000331 toxic Toxicity 0.000 title claims abstract description 28
- 108090000623 proteins and genes Proteins 0.000 title claims description 128
- 230000002110 toxicologic effect Effects 0.000 title abstract description 16
- 230000001575 pathological effect Effects 0.000 title abstract description 14
- 150000001875 compounds Chemical class 0.000 claims abstract description 59
- 238000009396 hybridization Methods 0.000 claims abstract description 45
- 238000012360 testing method Methods 0.000 claims abstract description 36
- 210000004962 mammalian cell Anatomy 0.000 claims abstract description 26
- 230000002588 toxic effect Effects 0.000 claims abstract description 19
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 12
- 210000004027 cell Anatomy 0.000 claims description 40
- 108020004999 messenger RNA Proteins 0.000 claims description 37
- 241000124008 Mammalia Species 0.000 claims description 25
- 230000014509 gene expression Effects 0.000 claims description 22
- 102000004169 proteins and genes Human genes 0.000 claims description 22
- 239000012634 fragment Substances 0.000 claims description 21
- 210000001519 tissue Anatomy 0.000 claims description 21
- 210000000056 organ Anatomy 0.000 claims description 20
- 239000002299 complementary DNA Substances 0.000 claims description 18
- 241000282414 Homo sapiens Species 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 16
- 230000000694 effects Effects 0.000 claims description 14
- 238000012216 screening Methods 0.000 claims description 12
- 231100000167 toxic agent Toxicity 0.000 claims description 12
- 239000003440 toxic substance Substances 0.000 claims description 11
- 108091034117 Oligonucleotide Proteins 0.000 claims description 9
- 150000007523 nucleic acids Chemical group 0.000 claims description 7
- 230000001988 toxicity Effects 0.000 claims description 7
- 231100000419 toxicity Toxicity 0.000 claims description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 6
- 230000008859 change Effects 0.000 claims description 6
- 238000009509 drug development Methods 0.000 claims description 6
- 238000002372 labelling Methods 0.000 claims description 6
- 238000001727 in vivo Methods 0.000 claims description 5
- 241000894007 species Species 0.000 claims description 5
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 4
- 230000002068 genetic effect Effects 0.000 claims description 3
- 241000282465 Canis Species 0.000 claims description 2
- 241000283984 Rodentia Species 0.000 claims description 2
- 108700019146 Transgenes Proteins 0.000 claims description 2
- 238000003745 diagnosis Methods 0.000 claims description 2
- 230000037213 diet Effects 0.000 claims description 2
- 235000005911 diet Nutrition 0.000 claims description 2
- 238000010839 reverse transcription Methods 0.000 claims description 2
- 230000002103 transcriptional effect Effects 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims 2
- 244000000010 microbial pathogen Species 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 230000002411 adverse Effects 0.000 abstract description 2
- 230000001819 effect on gene Effects 0.000 abstract description 2
- 239000000523 sample Substances 0.000 description 16
- 239000007787 solid Substances 0.000 description 16
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 238000002493 microarray Methods 0.000 description 11
- 230000012010 growth Effects 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 231100000334 hepatotoxic Toxicity 0.000 description 7
- 230000003082 hepatotoxic effect Effects 0.000 description 7
- 108091033319 polynucleotide Proteins 0.000 description 7
- 102000040430 polynucleotide Human genes 0.000 description 7
- 239000002157 polynucleotide Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 206010019851 Hepatotoxicity Diseases 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 210000000601 blood cell Anatomy 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 231100000304 hepatotoxicity Toxicity 0.000 description 6
- 230000007686 hepatotoxicity Effects 0.000 description 6
- 230000001717 pathogenic effect Effects 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 108091060211 Expressed sequence tag Proteins 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 229940000406 drug candidate Drugs 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 231100000027 toxicology Toxicity 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 108700039887 Essential Genes Proteins 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 238000003491 array Methods 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 239000002547 new drug Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000003466 anti-cipated effect Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 230000003100 immobilizing effect Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 210000001995 reticulocyte Anatomy 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000007877 drug screening Methods 0.000 description 2
- 231100000584 environmental toxicity Toxicity 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 231100000234 hepatic damage Toxicity 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000008818 liver damage Effects 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000000329 molecular dynamics simulation Methods 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 231100000255 pathogenic effect Toxicity 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000012340 reverse transcriptase PCR Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 230000008791 toxic response Effects 0.000 description 2
- 231100000759 toxicological effect Toxicity 0.000 description 2
- SJECZPVISLOESU-UHFFFAOYSA-N 3-trimethoxysilylpropan-1-amine Chemical compound CO[Si](OC)(OC)CCCN SJECZPVISLOESU-UHFFFAOYSA-N 0.000 description 1
- ZOCUOMKMBMEYQV-GSLJADNHSA-N 9alpha-Fluoro-11beta,17alpha,21-trihydroxypregna-1,4-diene-3,20-dione 21-acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ZOCUOMKMBMEYQV-GSLJADNHSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010007269 Carcinogenicity Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- 241000403354 Microplus Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 238000012356 Product development Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 239000007997 Tricine buffer Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000003181 biological factor Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- 230000003683 cardiac damage Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000012398 clinical drug development Methods 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 238000013481 data capture Methods 0.000 description 1
- 238000007418 data mining Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000009274 differential gene expression Effects 0.000 description 1
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 231100000206 health hazard Toxicity 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100000499 nonhepatotoxic Toxicity 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000002186 photoactivation Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 238000012910 preclinical development Methods 0.000 description 1
- 229940048207 predef Drugs 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000000275 quality assurance Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- VGTPCRGMBIAPIM-UHFFFAOYSA-M sodium thiocyanate Chemical compound [Na+].[S-]C#N VGTPCRGMBIAPIM-UHFFFAOYSA-M 0.000 description 1
- 101150065190 term gene Proteins 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
L'invention porte sur un procédé d'évaluation des effets pathologiques de stimuli ou de réactifs environnementaux sur des cellules de mammifère par identification sur une grille d'ADN d'un motif d'hybridation en forme "d'empreinte digitale". Ledit motif est caractéristique de différents stimuli ou réactifs environnementaux chimiques ou structurels présentant un effet adverse commun sur la transcription des gènes. Différentes substances expérimentales sont testées pour rechercher un effet toxique similaire en comparant leur motif d'hybridation sur une grille similaire avec l'empreinte digitale.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6624197P | 1997-11-20 | 1997-11-20 | |
| US60/066,241 | 1997-11-20 | ||
| PCT/GB1998/003445 WO1999027090A1 (fr) | 1997-11-20 | 1998-11-20 | Procede d'evaluation des effets toxiques et pathologiques de stimuli environnementaux sur la transcription des genes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2310621A1 true CA2310621A1 (fr) | 1999-06-03 |
Family
ID=22068220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002310621A Abandoned CA2310621A1 (fr) | 1997-11-20 | 1998-11-20 | Procede d'evaluation des effets toxiques et pathologiques de stimuli environnementaux sur la transcription des genes |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1032663A1 (fr) |
| JP (1) | JP2001524311A (fr) |
| AU (1) | AU1166199A (fr) |
| CA (1) | CA2310621A1 (fr) |
| WO (1) | WO1999027090A1 (fr) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6593084B2 (en) | 1998-10-13 | 2003-07-15 | Robert E. Bird | Carcinogen assay |
| US6852845B1 (en) * | 1999-11-22 | 2005-02-08 | Curagen Corporation | Method of identifying toxic agents using NSAID-induced differential gene expression in liver |
| AU2001268399A1 (en) * | 2000-06-14 | 2001-12-24 | Vistagen, Inc. | Toxicity typing using mesenchymal stem cells |
| KR100865664B1 (ko) * | 2000-06-14 | 2008-10-29 | 비스타겐 인코포레이티드 | 간 줄기 세포를 사용하는 독성 타이핑 |
| US7590493B2 (en) | 2000-07-31 | 2009-09-15 | Ocimum Biosolutions, Inc. | Methods for determining hepatotoxins |
| JP2002065259A (ja) * | 2000-08-24 | 2002-03-05 | Shinya Watanabe | 核酸標識方法および核酸標識用キット |
| FR2819524B1 (fr) * | 2001-01-18 | 2003-07-04 | Antonios Vekris | Hybridation differentielle par competition |
| WO2002059560A2 (fr) * | 2001-01-23 | 2002-08-01 | Gene Logic, Inc. | Methode et systeme de prediction de l'activite biologique, y compris de la toxicologie et de la toxicite de substances |
| EP1392871A4 (fr) * | 2001-05-22 | 2006-04-19 | Gene Logic Inc | Modelisation en toxicologie moleculaire |
| KR20020096559A (ko) * | 2001-06-21 | 2002-12-31 | 이준호 | 알코올에 의해 특이적으로 그 전사발현이 유도되거나저해되는 알코올 민감성 유전자 발굴 |
| AU2002365904A1 (en) * | 2001-07-10 | 2003-09-04 | Gene Logic, Inc. | Cardiotoxin molecular toxicology modeling |
| US7447594B2 (en) | 2001-07-10 | 2008-11-04 | Ocimum Biosolutions, Inc. | Molecular cardiotoxicology modeling |
| US20050112573A1 (en) * | 2001-08-24 | 2005-05-26 | Hitoshi Iwahashi | Method of detecting toxic substance |
| EP1476747A4 (fr) * | 2002-01-31 | 2008-06-11 | Ocimum Biosolutions Inc | Modelisation d'hepatotoxicologie moleculaire |
| US7469185B2 (en) | 2002-02-04 | 2008-12-23 | Ocimum Biosolutions, Inc. | Primary rat hepatocyte toxicity modeling |
| WO2004009765A2 (fr) * | 2002-07-19 | 2004-01-29 | Althea Technologies, Inc. | Strategies pour l'analyse de l'expression genique |
| AU2003284921A1 (en) * | 2002-10-22 | 2004-05-13 | Iconix Pharmaceuticals, Inc. | Reticulocyte depletion signatures |
| JP2007501617A (ja) * | 2003-08-07 | 2007-02-01 | ジーン ロジック インコーポレイテッド | 初代ラット肝細胞毒性モデリング |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0680517T4 (da) * | 1993-01-21 | 2005-05-02 | Harvard College | Fremgangsmåde og diagnostiske sæt til bestemmelse af en forbindelses toksicitet under anvendelse afstress-promotorer fra pattedyr |
| WO1997013877A1 (fr) * | 1995-10-12 | 1997-04-17 | Lynx Therapeutics, Inc. | Mesure de profils d'expression genique pour evaluer la toxicite |
| US6156502A (en) * | 1995-12-21 | 2000-12-05 | Beattie; Kenneth Loren | Arbitrary sequence oligonucleotide fingerprinting |
-
1998
- 1998-11-20 CA CA002310621A patent/CA2310621A1/fr not_active Abandoned
- 1998-11-20 AU AU11661/99A patent/AU1166199A/en not_active Abandoned
- 1998-11-20 EP EP98954606A patent/EP1032663A1/fr active Pending
- 1998-11-20 JP JP2000522232A patent/JP2001524311A/ja active Pending
- 1998-11-20 WO PCT/GB1998/003445 patent/WO1999027090A1/fr not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP1032663A1 (fr) | 2000-09-06 |
| JP2001524311A (ja) | 2001-12-04 |
| AU1166199A (en) | 1999-06-15 |
| WO1999027090A1 (fr) | 1999-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0743989B1 (fr) | Procédé d'identifcation des genes exprimés differentes | |
| CA2310621A1 (fr) | Procede d'evaluation des effets toxiques et pathologiques de stimuli environnementaux sur la transcription des genes | |
| US6160105A (en) | Monitoring toxicological responses | |
| EP1235933A2 (fr) | Marqueurs de reaction toxicologique | |
| CA2485968A1 (fr) | Technique de prevision de maladies auto-immunes | |
| US6258536B1 (en) | Expression monitoring of downstream genes in the BRCA1 pathway | |
| US6403778B1 (en) | Toxicological response markers | |
| EP1108067A2 (fr) | Marqueurs de reaction toxicologique | |
| US20030224407A1 (en) | Methods for identifying the toxic/pathologic effect of environmental stimuli on gene transcription | |
| JP2001505417A (ja) | 生物の成長に必須の遺伝子の同定方法 | |
| US6160104A (en) | Markers for peroxisomal proliferators | |
| US7091033B2 (en) | Array of toxicologically relevant canine genes and uses thereof | |
| CN113416775A (zh) | 一种心血管疾病相关snp位点引物组合物及应用 | |
| US20090143238A1 (en) | Oligonucleotide matrix and methods of use | |
| JP2004500076A (ja) | 新生児スクリーニングのためのジーンチップ | |
| US20070026408A1 (en) | Materials and methods for analysis of atp-binding cassette transporter gene expression | |
| WO2002082969A2 (fr) | Diagnostics et therapeutiques pour le glaucome, les maladies degeneratives de la retine et les maladies cardio-vasculaires effectues sur la base de nouveaux acides nucleiques et nouvelles formes proteiniques de la myociline (myoc) | |
| US20080076672A1 (en) | Methods for Identifying Genes Essential to the Growth of an Organism | |
| KR101760246B1 (ko) | 신규한 slco2b1 다형성 마커 및 이의 용도 | |
| Baumgartner et al. | Comparative Genomic Hybridization (CGH) in Genotoxicology | |
| US20040118060A1 (en) | Ion channel arrays | |
| EP1005653A1 (fr) | Procede de realisation d'echantillotheque soustractive | |
| US20070196837A1 (en) | Methods for mapping signal transduction pathways to gene expression programs | |
| US20030148288A1 (en) | Colorimetric genetic test for clinically significant TNF polymorphism and methods of use thereof | |
| Gül | Development of an Oligonucleotide Based Sandwich Array Platform for the Detection of Transgenic Elements From Plant Sources Using Labal-Free PCR Products |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |